Attempts to downregulate ovarian function in the bitch by applying a GnRH agonist implant in combination with a 3ß-hydroxysteroid-dehydrogenase blocker; a pilot study.
3-Hydroxysteroid Dehydrogenases
/ antagonists & inhibitors
Animals
Dihydrotestosterone
/ administration & dosage
Dogs
Down-Regulation
Drug Implants
Enzyme Inhibitors
/ administration & dosage
Estradiol
Estrous Cycle
/ drug effects
Female
Gonadotropin-Releasing Hormone
/ agonists
Hydrocortisone
/ blood
Luteinizing Hormone
Ovary
/ physiology
Progesterone
/ blood
Triptorelin Pamoate
/ administration & dosage
Deslorelin
Dog
Estradiol-17β
LH
Ovary
Progesterone
Trilostane
Journal
Theriogenology
ISSN: 1879-3231
Titre abrégé: Theriogenology
Pays: United States
ID NLM: 0421510
Informations de publication
Date de publication:
15 Mar 2020
15 Mar 2020
Historique:
received:
03
07
2019
revised:
22
10
2019
accepted:
22
10
2019
pubmed:
16
11
2019
medline:
8
1
2021
entrez:
16
11
2019
Statut:
ppublish
Résumé
Approaches to downregulate ovarian function in the sexually mature bitch by applying slow release GnRH agonist implants are hampered by the initial stimulation of folliculogenesis (flare up) and the resulting side effects. The present pilot study was designed to test to what extent these effects can be suppressed by simultaneous treatment with the 3ß-hydroxysteroid-dehydrogenase (HSD3B) blocker trilostane (T). Treatment with T in 6-h intervals completely blocked adrenal cortisol production. However, in parallel and concomitant with the increase of LH, progesterone and estradiol levels increased, ending up in pro-estric steroid levels in two of the three dogs. Hormonal changes were reflected in the respective clinical symptoms. During the whole observation period the course of LH concentrations did not indicate downregulation of pituitary function as a result of treatment with the GnRH-agonist Suprelorin®, 4.7 mg. The incomplete inhibitory effect of T on the follicular production of sex steroids could be explained by an insufficient transfer of T into the follicular compartment or the existence of a HSD3B isoform in the dog ovary different from the adrenal enzyme. Concerning the lack of downregulation and when accounting for published data different pharmacodynamics/pharmacokinetic activities of GnRH-agonists should be taken into account.
Identifiants
pubmed: 31727388
pii: S0093-691X(19)30476-5
doi: 10.1016/j.theriogenology.2019.10.022
pii:
doi:
Substances chimiques
Drug Implants
0
Enzyme Inhibitors
0
Triptorelin Pamoate
08AN7WA2G0
Dihydrotestosterone
08J2K08A3Y
Gonadotropin-Releasing Hormone
33515-09-2
Progesterone
4G7DS2Q64Y
Estradiol
4TI98Z838E
Luteinizing Hormone
9002-67-9
3-Hydroxysteroid Dehydrogenases
EC 1.1.-
trilostane
L0FPV48Q5R
deslorelin
TKG3I66TVE
Hydrocortisone
WI4X0X7BPJ
Types de publication
Clinical Trial, Veterinary
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-180Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.